Perimeter Medical Imaging AI Hosts Two Poster Presentations at the College of American Pathologists 2022 Annual Meeting

Rhea-AI Summary

Perimeter Medical Imaging AI (OTC:PYNKF) announced significant findings at the College of American Pathologists Annual Meeting 2022. Their research highlights the use of the Perimeter S-Series Wide-Field Optical Coherence Tomography (OCT) system for real-time microstructural imaging across various tissues, including breast, kidney, and lung. Presentations addressed the intraoperative evaluation of tissue in head and neck surgery, supporting the device's potential to enhance surgical outcomes. The device offers 10x greater resolution than X-ray and 100x that of MRI, aligning with the company's mission to improve cancer surgery.

Positive

• Validation of Perimeter S-Series OCT for imaging across multiple tissue types presents growth opportunities.
• 10x greater image resolution than X-ray and 100x greater than MRI enhances clinical utility.
• Positive data presented at CAP22 may boost investor confidence and interest in the technology.

Negative

• None.

Research provides validation of wide-field Optical Coherence Tomography (OCT) for microstructural analysis of tissue from multiple organs and tissue types

TORONTO & DALLAS--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – announced two poster presentations at the Annual Meeting of the College of American Pathologists 2022 (CAP22), which took place October 8 to 11, 2022 in New Orleans, LA. The research presented validates the potential use of Perimeter S-Series OCT to intraoperatively image specimens across a variety of tissue types, such as breast, thyroid, kidney, liver, lung, colon, heart, pancreas, spleen, and adrenal glands:

• Validation of Wide-Field Optical Coherence Tomography for Microstructural Analysis of Tissue From Multiple Organs (Poster No. 108)
• Intraoperative Use of Wide-Field Optical Coherence Tomography to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx (Poster No. 170)

Andrew Berkeley, Perimeter’s Co-founder stated, “We were excited to present to leading pathologists at CAP22 with data that support the potential use of Perimeter’s OCT medical imaging technology across several tissue types, including the analysis of margins in head and neck surgery. This research helps demonstrate that Perimeter S-Series has the potential to be used in a variety of settings to help ‘bridge the gap’ between the surgeon’s need for immediate ‘real time’ info in the operating room with images that correlate to histological results, with a process that does not interfere with surgical procedures or final pathology.”

About Perimeter Medical Imaging AI, Inc. 
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter’s expected development activities and the expected details regarding Perimeter’s ongoing clinical trials are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2021, which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012006049/en/

Chris Scott

Chief Financial Officer

Perimeter Medical Imaging AI, Inc.

Investors: investors@perimetermed.com

Toll-free: 888-988-7465 (PINK)

Jodi Regts

Corporate Communications

Perimeter Medical Imaging AI, Inc.

Media: media@perimetermed.com

Mobile: 469-743-1834

Source: Perimeter Medical Imaging AI, Inc.

FAQ

What was presented by Perimeter Medical Imaging AI at CAP22?

Perimeter Medical Imaging AI presented research on the Perimeter S-Series OCT system, validating its use for microstructural analysis of various tissues.

What are the applications of the Perimeter S-Series OCT system?

The Perimeter S-Series OCT system is designed for intraoperative imaging of various tissues, including breast, thyroid, and oral cavity.

How does the imaging resolution of Perimeter's technology compare to traditional methods?

The S-Series OCT system provides 10x greater resolution than X-ray and 100x greater than MRI.

What is the significance of the findings presented by Perimeter Medical Imaging AI?

The findings support the potential of Perimeter's technology to improve surgical outcomes by providing real-time tissue analysis.

What ticker symbol is used for Perimeter Medical Imaging AI?

Perimeter Medical Imaging AI trades under the ticker symbol PYNKF on the OTC market.